Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company’s Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Member of the Executive Committee for Bayer Pharmaceuticals, as his successor, effective April 3, 2023. She will also join Vir’s Board of Directors.
- “George led the Company through a period of significant transformation, accelerated its growth and established a broad pipeline and strategy that we believe will support our long-term success.
- In 2022, Vir was named the fastest growing company on the 2022 Deloitte Technology Fast 500 .
- Prior to joining Vir, Dr. Scangos served as CEO and as a member of the Board of Biogen Inc. for six years.
- “Vir represents an amalgamation of the best of what science and commitment to patients have to offer.